References
- `1. Otte JB, de Ville de Goyet J, Reding R, Hausleithner V, Sokal E, Chardot C, et al. Sequential treatment of biliary atresia with Kasai portoenterostomy and liver transplantation: a review. Hepatology. 1994; 20: 41S-48S.
- 2. Perlmutter DH, Shepherd RW. Extrahepatic biliary atresia: a disease or a phenotype? Hepatology. 2002; 35:1297-304.
- 3. Chen L, Goryachev A, Sun J, Kim P, Zhang H, Phillips MJ, et al. Altered expression of genes involved in hepatic morphogenesis and fibrogenesis are identified by cDNA microarray analysis in biliary atresia. Hepatology. 2003; 38:567-76.10.1053/jhep.2003.50363
- 4. Chongsrisawat V, Chatchatee P, Samransamruajkit R, Vanapongtipagorn P, Chottivittayatarakorn P, Poovorawan Y. Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension. Pediatr Surg Int. 2003; 19:478-81.
- 5. Chongsrisawat V, Kongtawelert P, Tongsoongnoen W, Tangkijvanich P, Vejchapipat P, Poovorawan Y. Serum hyaluronan as a marker reflecting the severity of cirrhosis and portal hypertension in postoperative biliary atresia. Pediatr Surg Int. 2004; 20:773-7.10.1007/s00383-004-1141-7
- 6. Vejchapipat P, Theamboonlers A, Chaokhonchai R, Chongsrisawat V, Chittmittrapap S, Poovorawan Y. Serum hepatocyte growth factor and clinical outcome in biliary atresia. J Pediatr Surg. 2004; 39:1045-9.
- 7. Honsawek S, Chongsrisawat V, Vejchapipat P, Thawornsuk N, Tangkijvanich P, Poovorawan Y. Serum interleukin-8 in children with biliary atresia: relationship with disease stage and biochemical parameters. Pediatr Surg Int. 2005; 21:73-7.10.1007/s00383-004-1329-x
- 8. Honsawek S, Chongsrisawat V, Vejchapipat P, Thawornsuk N, Poovorawan Y. Association of serum levels of tissue inhibitors of metalloproteinase-1 with clinical outcome in children with biliary atresia. Asian Pac J Allergy Immunol. 2006; 24:161-6.
- 9. Friedman SL. Stellate cells: a moving target in hepatic fibrogenesis. Hepatology. 2004; 40:1041-3.10.1002/hep.20476
- 10. Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology. 2000; 32:1403-8.
- 11. Garcia-Monzon C, Sanchez-Madrid F, Garcia-Buey L, Garcia-Arroyo A, Garcia-Sanchez A, Moreno-Otero R. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology. 1995; 108:231-41.
- 12. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno- Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology. 2004; 39:1185-95.
- 13. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998; 27:1554-62.
- 14. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, et al. Hypoxia-induced VEGF and collagen expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002; 35:1010-21.10.1053/jhep.2002.32524
- 15. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999; 103:1231-6.
- 16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1:27-31.
- 17. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964-7.
- 18. Rosmorduc O, Wendum D, Corpechot C, Galy B, Sebbagh N, Raleigh J, et al. Hepatocellular hypoxiainduced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol. 1999; 155:1065-73.
- 19. Dvorak HF, Brown IF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hypermeability, and angiogenesis. Am J Pathol. 1995; 146:1029-39.
- 20. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000; 407:242-8.
- 21. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998; 77:956-64.
- 22. Webb NJA, Bottomley MJ, Watson CJ, Brenchley PEC. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci. 1998; 94:395-404.10.1042/cs0940395
- 23. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical evidence of platelet scavenging? Clin Cancer Res. 2000; 6:3147-52.
- 24. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut. 2001; 49:565-76.
- 25. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol. 2002; 160:641-54.
- 26. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, et al. JTE-522, a cyclooxygenase- 2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology. 2003; 125:556-71.
- 27. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002; 35:1010-2.
- 28. Ankoma-Sey V, Wang Y, Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology. 2000; 31:141-8.
- 29. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999; 77:527-43.
- 30. Mochida S, Ishikawa K, Toshima K, Inao M, Ikeda H, Matsui A, et al. The mechanisms of hepatic sinusoidal endothelial cell regeneration: a possible communication system associated with vascular endothelial growth factor in liver cells. J Gastroenterol Hepatol. 1998; 13 (Suppl):S1-S5.
- 31. Ishikawa K, Mochida S, Mashiba S, Inao M, Matsui A, Ikeda H, et al. Expressions of vascular endothelial growth factor in nonparenchymal as well as parenchymal cells in rat liver after necrosis. Biochem Biophys Res Commun. 1999; 254:587-93.
- 32. Jones MK, Szabo IL, Kawanaka H, Husain SS, Tarnawski AS. von Hippel-Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J. 2002; 16: 264-6.
- 33. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. Portal hypertension. J Hepatol. 2000; 32:141-56.10.1016/S0168-8278(00)80422-5
- 34. Bosch J, Pizcueta P, Feu F, Fernandez M, Garcia-Pagan JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am. 1992; 21:1-14.
- 35. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology. 2004; 126: 886-94.
- 36. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodes J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005; 43:98-103.10.1016/j.jhep.2005.02.022
- 37. Shi B, Wang X, Yang Z. Vascular endothelial growth factors and liver diseases. Hepatogastroenterology. 2001; 48:1145-8.
- 38. Aw MM, Mitry RR, Hughes RD, Dhawan A. Serum hepatocyte growth factor and vascular endothelial growth factor in children with acute liver failure. J Pediatr Gastroenterol Nutr. 2007; 44:224-7.
- 39. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer. 1999; 80:892-7.
- 40. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res. 2000; 6:3147-52.
- 41. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res. 1997; 3:2187-90.
- 42. Harrison P, Wilbourn B, Debili N, Vainchenker W, Breton-Gorius J, Lawrie AS, et al. Uptake of plasma fibrinogen into α granules of human megakaryocytes and platelets. J Clin Invest. 1989; 84:1320-4. 10.1172/JCI114300